Pediatric-type diffuse high-grade gliomas …

Elizabeth Finch MD

Neuro-Oncology

Updated 08.14.2024
Released 04.29.2003
Expires For CME 08.14.2027

Pediatric-type diffuse high-grade gliomas (excluding diffuse midline gliomas)

Author: Elizabeth Finch MD

See Contributor Disclosures

Editor: Roger J Packer MD

Pediatric-type diffuse high-grade gliomas (excluding diffuse midline gliomas)

In This Article

Quick Link

Introduction

Overview

Pediatric-type diffuse high-grade gliomas continue to be one of the most difficult types of brain tumors to treat in children, given their infiltrative nature and low probability of successful gross total resection. In this article, the authors present a comprehensive review of the basic principles and practices underlying the causes, diagnosis, treatment, and outcomes of pediatric-type diffuse high-grade glioma. The authors also present updated therapeutic and molecular research advancements in these childhood tumors.

Key points

	• Molecular characterization of pediatric-type diffuse high-grade glioma is explored.
	• There are four distinct subtypes of pediatric-type diffuse high-grade glioma with different, distinct characteristics.
	• The diffuse nature of these tumors makes gross total resection impossible, which contributes greatly to the poor prognosis.
	• Survival remains poor for most of these tumors; however, new clinical trials are being investigated.

Historical note and terminology

Brain tumor classification began in the 1920s. The proposed classification system for gliomas was based on the idea that gliomas originated from central nervous system cells arrested at various stages of development (02). Recognizing that brain tumors contained heterogeneous cell populations, gliomas were classified based on the morphological appearance and presumed histogenesis of the predominant cell type. Most classification schemes have been constructed to various degrees around the conceptual framework introduced by Bailey and Cushing (45; 28). Other classifications have proposed that glial cells become progressively more anaplastic rather than undergo a single neoplastic transformation to malignant glioma (47). This concept has led to the proposal to simplify brain tumor classification to reflect the degree of anaplasia present by grading the tumors from grade I (benign) to grade IV (malignant). However, with advancements in tumor biology genetics, it is now known that histopathology alone cannot provide prognostic value to the diagnosis. As a result, in 2016, an international collaboration of renowned scientists and clinicians revised the current World Health Organization classifications by including molecular parameters (32).

This was further emphasized in the most recent version of the WHO Classification of Tumors of the Central Nervous System, version 5, which was released in 2021 and subdivided pediatric-type diffuse high-grade glioma into four distinct subtypes: diffuse midline glioma; H3 K27-altered (which will be discussed separately), diffuse hemispheric glioma; H3 G34-mutant, diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; and infant-type hemispheric glioma (33). An account of the historical evolution of glioma terminology has been previously provided in much greater detail (57).

Clinical manifestations

Presentation and course

• Given the involvement of various parts of the brain by pediatric-type diffuse high-grade gliomas, the presenting symptoms vary greatly.

Brain tumors can often be localized based on the symptoms they provoke; however, this is not universally true of diffuse pediatric high-grade gliomas. Depending on the subtype, these tumors may be vastly infiltrative or relatively well-circumscribed. The infant type of diffuse high-grade glioma is the most likely subtype to be circumscribed, but the diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype can also be circumscribed (17). Headaches are a leading symptom when the tumor causes a decreased flow of cerebral spinal fluid, leading to increased intracranial pressure (36; 48; 04) and may be part of the classic triad of increased intracranial pressure, lethargy, and vomiting. The headaches are usually worse when waking up and improve during the day. School-aged children more commonly report vague, intermittent headaches and fatigue. They may have a declining academic performance and exhibit personality changes. Infants may present with irritability, failure to thrive, anorexia, developmental delay, or regression (44). On physical examination, raised intracranial pressure is best appreciated as papilledema on fundoscopic evaluation; however, this may present only as optic pallor in infants with open cranial sutures.

Although brain tumors are found in 1% to 3% of children with new-onset seizures, seizures occur in approximately 20% of patients with supratentorial malignant gliomas (36). Supratentorial tumors were more commonly associated with seizures than infratentorial tumors. Delayed seizure onset, lesser seizure frequency with focal weakness, and signs of increased intracranial pressure were noted more in malignant tumors (52). Hypothalamic tumors may be associated with neuroendocrine abnormalities, growth hormone deficiency, diabetes insipidus, and precocious pubertal development. These tumors may also impinge on the optic chiasm, resulting in optic atrophy and visual deficits. Patients with diencephalic tumors may present with the classic diencephalic syndrome (emesis, emaciation, and unusual euphoria), but the syndrome is rare in children older than 3 years.

Prognosis and complications

In most children with pediatric-type diffuse high-grade glioma, outcomes are poor. Most members of this group are considered to have aggressive tumors with very poor overall survival (17).

Diffuse hemispheric glioma, H3 G34-mutant. In a study of 135 patients diagnosed with H3 G34-mutant diffuse hemispheric glioma between 2012 and 2021, the median overall survival was 17.3 months; those patients with gross total or near total resection or older age had improved survival (11). Surprisingly, approximately half of the patients in this study were able to have a gross or near total resection, suggesting that this type of glioma may not be as infiltrative. A better prognosis is observed in those tumors with MGMT promoter methylation (17).

Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype. Within this subgroup, those tumors with MYCN amplification and pontine location have the worst prognosis, with a median survival of fewer than 2 months (17). The RTK1 subgroup is often seen in patients who have had prior radiation, and this portends a worse prognosis in this setting (17).

Infant-type hemispheric glioma. Infant-type hemispheric gliomas have a much better prognosis than other pediatric-type high-grade gliomas, with a 60% to 70% overall survival (12).

Given that this is a new tumor classification, the overall and event-free survival has yet to be accurately established for each subgroup. Using previous classification schemas, the consensus was that as a group, supratentorial malignant gliomas have a less than 30% 5-year survival rate (54), and this likely translates to pediatric-type diffuse high-grade gliomas as well. The one exception to this poor prognosis is the infant-type hemispheric glioma in which specific fusions may respond to targeted therapy and, thus, have a better overall prognosis (17).

A comprehensive review of Surveillance, Epidemiology, and End Results (SEER) data consisted of 6212 patients younger than 20 years of age at diagnosis of glioma (1973 to 2005) in four age categories: less than 1 year, 1 to 3 years, 3 to 5 years, and 5 to 20 years (43). Tumor grade emerged as the most significant independent prognostic factor in all age groups except the youngest, in which extent of resection was most significant. A SEER data review on 302 pediatric patients with glioblastoma reveals an overall median survival of 20 months and 2-year survival rate of 46.9%. When broken down into age categories, those aged 0 to 4 years had the highest median survival of 59 months; 5 to 9 years was 12 months (24.5% 2-year survival rate), 10 to 14 years was 19 months (35.8% 2-year survival rate), and 15 to 19 years was 23 months (48% 2-year survival rate). Those with supratentorial tumors had better survival outcomes compared to infratentorial tumors (median overall survival 22 months, 45.4% 2-year survival rate, vs. 14 months, 13.5% 2-year survival rate).

Clinical vignette

A 12-year-old male presented to the emergency room with several months of worsening coordination that left him unable to play his favorite sport of soccer, followed by progressive right-sided weakness and slurred speech. An MRI showed a diffuse, expansile T2 hyperintense signal that involved the corpus callosum and extended into the right cerebral hemisphere and cortical spinal tracts. The differential diagnosis at that time was a primary glial neoplasm and, less likely, lymphoma, given a lack of significant enhancement. He underwent needle biopsy, and pathology showed an infiltrating glioma with brisk mitotic activity, which, according to the most recent WHO classification, fell under the subtype of a diffuse pediatric high-grade glioma, H3-wildtype and IDH-wildtype. Given the high grade of this tumor, he immediately started intensity-modulated photon radiation therapy to the areas of the brain that contained tumor for a total of 60 Gy. He was also concurrently treated with oral temozolomide as per the Children’s Oncology Group study ACNS0423. Molecular testing on the tumor returned with PDGFRA N468S-subclonal (but only a 1% variant allele frequency), PIK3R1 E462_R465del (45.8% variant allele frequency), ATR 1774fs*3, STAG2 L813, TERT promoter -146C>T. Unfortunately, no successful targeted therapies were available at that time.

At the completion of radiation, MRI showed a slight increase in the T2/FLAIR hyperintensity in the subcortical white matter of the frontal lobes. Four weeks after the completion of radiation, he started maintenance chemotherapy with 1 day of lomustine and 5 days of temozolomide, with plans to repeat this every 6 weeks. He remained steroid-dependent, so a dose of bevacizumab was given in an attempt to allow for more rapid weaning of steroids. Unfortunately, he then developed right-sided paralysis and refractory seizures, requiring admission to the hospital and multiple antiepileptics. MRI obtained on admission did not show any infarct or hemorrhage at that time, and the overall tumor burden was stable.

Over the course of the next month, the tumor showed increased infiltration into the left cerebral hemisphere with a midline shift to 11 mm. A shunt was placed, which did help with some symptoms. Previous chemotherapy was discontinued, and the patient was started on oral metronomic chemotherapy with celecoxib, fenofibrate, valproic acid, and alternating cyclophosphamide and etoposide. After 4 months of metronomic chemotherapy, there was an improvement in the mass effect caused by the tumor, and after 8 months of this therapy, there was a significant decrease in enhancement along the corpus callosum, left peritrigonal white matter, and the centrum semiovale. There was still a T2 hyperintense signal throughout the cerebral hemisphere, corpus callosum, and right centrum semiovale but almost complete resolution of any midline shift. He eventually developed hemorrhagic cystitis from the cyclophosphamide, so it was replaced with temozolomide. Unfortunately, after 15 cycles of metronomic chemotherapy, and 18 months after initial diagnosis, the patient died from his disease.

Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype in a teenager

Progression of Axial T2 MRI findings in a 13-year-old male with a diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype. (a, b) Obtained at time of diagnosis, MRI shows a diffuse, expansile T2 hyperintense sign...

Biological basis

Etiology and pathogenesis

When discussing the etiology and pathogenesis of pediatric-type diffuse high-grade gliomas, it is best to separate them into their subtypes.

Diffuse hemispheric glioma, H3 G34-mutant. The H3 G34-mutant diffuse hemispheric glioma is triggered by a point mutation in the histone H3.3 gene at codon 34, which results in a glycine being replaced most commonly by an arginine, but it can also be replaced by a valine (17). It is hypothesized that the tumors are neuronal in origin (42). The majority of these tumors will have mutations in TP53 and a loss of ATRX, and they will lack OLIG2 expression (23).

Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype. This particular subgroup of pediatric-type diffuse high-grade gliomas is not as cohesive. To fall into this category, a tumor must be high grade as assessed by the pathologist, not have any histone mutations on molecular testing, and fall into one of three subgroups when methylation testing is performed (17). The three methylation subgroups are RTK1, RTK2, and MYCN (17). They commonly have mutations in MYCN, EGFR, NF1, TP53, and PDGFRA (40). When tumors with these characteristics appear in patients with cancer predisposition syndromes, such as Li Fraumeni syndrome, they should be viewed as completely different tumors because they often behave differently in that specific patient population (42). The majority of tumors that were previously classified as gliomatosis cerebri would now fall in this category based on molecular findings (39).

Infant-type hemispheric glioma. Infant-type hemispheric gliomas originate from astrocytes and are not associated with histone mutations (17). These tumors that occur in the youngest of patients frequently express fusions that involve the following receptor tyrosine kinases: MET, NTRK, ALK, and ROS1 (40). The diagnosis is made based on a characteristic fusion or specific methylation clustering (17). There is a small subset of infant-type hemispheric gliomas that do not have high-grade features (17).

Diagnostic workup

	• MRI is the gold standard in determining if a patient has a brain tumor.
	• To determine the exact diagnosis in most tumor types, including pediatric-type diffuse high-grade glioma, obtaining tissue is necessary.

Imaging studies. Head CT or preferably MRI with and without contrast must be performed in all patients suspected of having a brain tumor. On CT, malignant gliomas typically appear as irregularly shaped lesions with partial contrast enhancement and peritumoral edema with or without mass effect (29). MRI is also useful by better demonstrating the anatomic origin and extent of tumors. MRI is the imaging modality of choice for detecting disseminated spinal cord lesions and should be performed in all patients with suspected pediatric-type diffuse high-grade glioma. A postoperative MRI or CT is required to measure the extent of surgical resection and detect residual disease. Postoperative MRI or CT evaluation must be performed within 72 hours of surgery to delineate residual tumor from the postsurgical inflammatory changes that are visualized at this time. Advances in imaging using a technique called diffusion time-dependent MRI has shown promise in differentiating between low-grade and high-grade gliomas, but further validation is needed (56). Although certain types of pediatric-type diffuse high-grade gliomas are more common in certain locations in the brain, imaging alone is not diagnostic (41).

CSF cytological examination. Lumbar puncture may be useful in malignant gliomas for detecting microscopic leptomeningeal dissemination if clinically or radiographically suspected. CT imaging or MRI must be performed before the lumbar puncture to rule out the presence of hydrocephaly in those patients suspected of having a brain tumor. Hydrocephaly places the patient at risk for herniation as a consequence of the procedure. In general, the lumbar puncture is deferred for up to 2 weeks postoperatively to avoid identifying contaminating tumor cells that may have disseminated due to surgery.

Biopsy. Biopsy, whether a stereotactic needle biopsy or open biopsy, depending on the recommendations of the neurosurgeon, should be obtained if safely possible. Enough tissue should be procured to allow for morphologic diagnosis but also molecular testing and oftentimes methylation profiling as well. The characteristics that define each of the subtypes of pediatric-type diffuse high-grade glioma have been discussed previously.

Management

	• Although gross total resection is the goal for most brain tumors, this is impossible in the majority of pediatric-type diffuse high-grade gliomas due to their infiltrative nature, making radiation, chemotherapy, and other targeted therapies even more important.
	• A standard of care for pediatric-type diffuse high-grade gliomas, beyond surgery and radiation, has not been established; thus, it is recommended that patients be enrolled in clinical trials whenever possible.

Surgery. In pediatric-type diffuse high-grade gliomas, surgery alone is not curative but is necessary for diagnosis. Enough tissue must be obtained to send for molecular testing and, oftentimes, methylation profiling. Debulking can be considered especially for symptomatic relief but should be done by a pediatric-trained neurosurgeon.

Radiotherapy. Radiation therapy is often used for the upfront treatment of diffuse hemispheric glioma, H3 G34-mutant tumors, and diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype. Radiation is not used in infant-type hemispheric glioma given the young age of these patients and the desire to avoid radiation in the early stages of brain development (typically 3 years and younger) (12). Postoperative local (2 to 4 cm margin around the area of edema defined by imaging) or wide-field irradiation to 50 to 60 Gy is the mainstay of therapy for supratentorial malignant gliomas (26). If the tumor is disseminated, then craniospinal radiation should be used. The radiation modality should be discussed with an experienced pediatric radiation oncologist as each modality has its pros and cons.

Chemotherapy. Because the entity pediatric-type diffuse high-grade gliomas was only established in 2021, much of the data available on the use of chemotherapy concerns the broader category of pediatric malignant gliomas. Children with malignant gliomas appear to benefit from the addition of adjuvant chemotherapy to postoperative radiotherapy, although the extent of this benefit remains unclear. Early phase II and III trials with single-agent and multiagent chemotherapy demonstrated little or no impact on the overall survival despite showing objective response rates as high as 45% (30).

A Children’s Cancer Group trial with prednisone, lomustine (CCNU), and vincristine following postoperative radiotherapy reported a 5-year progression-free survival of 46% versus 18% with radiotherapy alone (49). However, a subsequent trial comparing pCV to the “8-drugs-in-1-day” regimen showed no significant differences in survival between the two groups, and the progression-free survival associated with pCV (26%) was substantially inferior to that noted in the original study (14). Furthermore, a review of the histology from the initial study with pCV suggested that a significant proportion of patients (69/250) did not fit the central consensus definition of malignant glioma. The Pediatric Oncology Group completed a study with adjuvant cisplatin and carmustine versus cyclophosphamide and vincristine following postoperative radiotherapy. The 5-year overall survival between the groups was 27% (± 9%) and 7% (± 7%) respectively.

Multiple trials utilizing neoadjuvant chemotherapy with a variety of regimens, including cisplatin and cytosine arabinoside; carboplatin, ifosfamide, or cyclophosphamide with etoposide; and procarbazine, have been uniformly disappointing (46). The report from the Children’s Oncology Group of a phase II trial (CCG 9933) randomizing between three separate high-dose chemotherapy regimens consisting of carboplatin/etoposide, ifosfamide/etoposide, or cyclophosphamide/etoposide prior to radiation failed to show any significant improvement in overall survival (24% +/- 5% at 5 years), and outcome did not differ between groups. The 5-year, event-free survival rate for all patients was 8% +/- 3% (35). In a report from the German study HIT-GBM-C utilizing radiation and simultaneous intensive multiagent chemotherapy, the 5-year overall survival rate for patients with complete resection was 63% +/- 12% SE, compared with 17% +/- 10% SE for the historical control group (P = .003), suggesting for the first time a therapeutic advantage with the addition of chemotherapy (55).

High-dose chemotherapy with autologous bone marrow or stem cell rescue has also been attempted in this population (13; 16; 21). In a study, objective responses were observed in 4 of 14 assessable patients treated with thiotepa and etoposide followed by autologous bone marrow rescue for malignant glioma (16). All of these patients (28%) remained free of disease for at least 3 years after autologous bone marrow rescue. A study using carmustine, thiotepa, and etoposide followed by autologous bone marrow rescue for 11 patients with malignant glioma demonstrated a 46% 2-year survival rate (21). In a Children’s Oncology Group study, myeloablative chemotherapy with autologous marrow rescue produced durable remissions in children with recurrent malignant gliomas in the setting of minimal residual tumor burden achieved surgically and was superior to conventional chemotherapy (15).

Despite the promising response rates reported, the toxicity associated with these regimens has been excessively high (5% to 15% toxic death rate due to treatment). In an effort to reduce toxicity, investigations have used multiple cycles of somewhat lower doses of chemotherapy followed by peripheral blood stem cell support (25). To a great extent, this has decreased transplant-related complications; however, the data relating to the maintenance of treatment efficacy are still premature, and the role of high-dose chemotherapy in the treatment of primary malignant gliomas remains undefined.

The use of temozolomide alone in pediatric patients has been less promising (31; 06). Because the use of concomitant radiation and temozolomide showed an overall survival benefit in newly diagnosed adult glioblastoma patients (51), several studies have been done to see if the same results are seen in pediatric high-grade glioma but have, thus far, failed to demonstrate a benefit on overall survival (09; 07). Another Phase II study by the Children's Oncology Group of children with high-grade gliomas showed that the addition of lomustine to temozolomide as adjuvant therapy improved outcomes compared to patients treated with temozolomide alone (09; 24); however, the study lacked treatment randomization and there was a substantial increase in hematologic toxicities (22).

An international phase 2 randomized controlled trial (HERBY) evaluated the use of concomitant and adjuvant temozolomide with/without bevacizumab (an anti-VEGF antibody) in pediatric high-grade glioma, with results showing that the addition of bevacizumab did not increase event-free survival and was associated with increased toxicity (20; 22). Currently, clinical trials are still underway to determine the most effective regimen.

Targeted therapy. The NTRK inhibitor larotrectinib has been successful in some patients with infantile high-grade glioma with NTRK fusions and was not associated with serious adverse side effects (12). Attempts have been made to use EGFR inhibitors in EGFR-amplified high-grade gliomas, but, unfortunately, this has not been successful at stopping tumor growth. However, newer EGFR inhibitors, such as osimertinib, may have better luck penetrating the blood-brain barrier (08). In a subset of six patients with PDGFRA-altered pediatric high-grade gliomas, targeting PDGFRA with dasatinib and also using an mTOR inhibitor seemed to prolong survival, but clinical trials are needed (38).

Other biological-based clinical trials are also currently being investigated. Histone deacetylase inhibitors, such as valproic acid, are well tolerated and have an encouraging response rate in heavily pretreated patients (37). Other histone deacetylase inhibitors currently being investigated include vorinostat and panobinosat, as well as BET bromodomain inhibitors such as BMS-986158 (22).

Immunotherapy. One of the mechanisms of cancer cells’ proliferative growth is their ability to evade the body’s immune detection system. The advent of immunotherapy in melanoma, lung, and other cancers has significantly impacted the treatment of these cancers. It has been theorized that tumors with high mutational burden respond better to immunotherapy; however, pediatric cancers generally harbor a lower mutational burden. One of the few exceptions is the acquired hypermutator phenotype associated with constitutional mismatch repair deficiency, which is present in less than 5% of patients with high-grade glioma. Immune checkpoint inhibitors such as programmed cell death-1 receptor monoclonal antibody (nivolumab) have been shown to have a promising role in this subset and are being studied in children with newly diagnosed or recurrent high-grade glioma with and without ipilimumab, a human cytotoxic T-lymphocyte antigen (05).

Autologous dendritic cell vaccination has shown promise in adult glioblastoma and is currently undergoing clinical trials (01). This process involves isolating monocytes from patients, maturing them with cytokines into dendritic cells, loading dendritic cells with appropriate tumor antigens in vitro, and infusing them back into patients to activate their immune system. According to clinicaltrials.gov, a clinical trial using a CMV dendritic cell vaccine given with GMCSF after priming with tetanus toxoid was conducted in 11 children, and nine of those children completed the trial (NCT03615404). One patient did not complete the trial because they died, and one vaccine did not pass quality assurance. The study showed that 90.9% of participants were able to make three or more vaccines from the pre-treatment leukapheresis, and no patients experienced unacceptable toxicity. The study was not designed to assess efficacy, so further trials will be needed.

Viral infection injected directly into tumor cells such as Herpes simplex virus 1716 (18), cytomegalovirus-specific cytotoxic T cells (34), or parvovirus H-1 (27) are being investigated. New viruses being studied in pediatric gliomas are in the early phases, including recombinant polio/rhinovirus delivered by convection-enhanced delivery. Intravenous reovirus as well as Newcastle disease virus are being evaluated. Other immunotherapies that are being studied for pediatric high-grade glioma include immunomodulatory agents such as thalidomide and pomalidomide. Chimeric antigen receptor T cells, which are T lymphocytes genetically engineered to target specific proteins with greater affinity, are currently in phase 1 trials, including children with recurrent high-grade glioma (22).

Finally, inhibitors against key survival pathways such as Akt and Notch signaling are also being investigated as potential therapeutic targets.

Potential therapeutic targets for pediatric supratentorial malignant gliomas

Multiple targets have been investigated for tumor-specific treatment therapies, most of which are currently undergoing clinical trials. (Contributed by Dr. Yoko Udaka.)

Tumor-treating fields. Tumor-treating fields are intermediate-frequency alternating current electric fields delivered to the tumor site via an array of electrodes applied directly to the scalp, acting as cytotoxic modalities by interfering with key components of cell division, specifically disrupting the spatial orientation of highly polarized molecules required for mitosis (03). The EF-14 trial showed that the addition of tumor-treating fields to standard-of-care adjuvant temozolomide following concurrent radiation and chemotherapy improved the 5-year overall survival in newly diagnosed glioblastoma patients (13% vs. 5%, p=.004) (50). In a feasibility study applying tumor-treating fields to five pediatric patients with high-grade glioma, all five patients tolerated tumor-treating fields well without treatment-limiting toxicities (19).

Table 1. Clinical Trials Available in the United States for Pediatric High-Grade Glioma as of July 31, 2024

Recruiting
	NCT05610891 - Trial looking at the use of CLR 131, a radio-iodinated therapy with a core phospholipid ether, and radiolabeled iodine-131 given IV for inoperable relapsed or refractory high-grade glioma
	NCT05553041 - Trial using 18F-fluciclovine PET imaging to see if it is possible to differentiate between progression and tumor change from therapy in high-grade glioma patients with concern for progression
	NCT04485559 - Phase 1 trial for recurrent high-grade glioma evaluating the safety of trametinib and everolimus
	NCT04573140 - Phase 1 trial assessing feasibility and safety of an RNA-LP vaccine in newly diagnosed high-grade glioma
	NCT04299191 - Trial evaluating LAM561 for recurrent or refractory high-grade glioma
	NCT04908709 - Trial for newly diagnosed high-grade glioma using spectroscopic MRI-guided proton therapy to assess metabolic change in the tumor
	NCT05298995 - Phase 1 study of anti-GD2 chimeric antigen receptor T cells in relapsed or refractory high-grade glioma
	NCT05099003 - A phase1/2 trial of selinexor and radiation therapy in newly diagnosed high-grade glioma
	NCT04978727 - A pilot study assessing the safety, tolerability, and immunological effects of SurVaxM for progressive or recurrent high-grade glioma
	NCT05835687 - Phase 1 trial evaluating autologous B7-H3-CAR T cells for relapsed or refractory high-grade glioma
	NCT05429502 - Phase 1/2 study assessing the efficacy and safety of ribociclib with topotecan and temozolomide for relapsed or refractory high-grade glioma
	NCT03213652 - Phase II trial of ensartinib in recurrent or refractory high-grade glioma with ALK or ROS1 genomic alterations
	NCT05278208 - Trial using lutetium Lu 177-dotatate, a radionuclide that blocks the type 2A somatostatin receptors and can be upregulated in recurrent or refractory pediatric high-grade glioma
	Active, not recruiting
	NCT03334305 - Trial assessing the safety of anti-tumor T cells and anti-tumor dendritic cell vaccine given to stimulate the patient’s own immune system to fight off the tumor cells in newly diagnosed high-grade glioma
	NCT01130077 - Pilot study assessing the safety of HLA-A2 restricted glioma antigen peptide vaccination and poly-ICLC for newly diagnosed, non-brainstem high-grade glioma
	NCT03128047 - Phase 1 trial for recurrent high-grade glioma evaluating the safety of NovoTTF-200A in combination with chemotherapy
	NCT03739372 - Pilot trial using molecular profiling to determine individualized treatment plans for newly diagnosed high-grade glioma
	NCT03398902 - Phase 1 study evaluating the safety and tolerability of CD40 agonistic monoclonal antibody APX005M in recurrent or refractory high-grade glioma
	NCT02323880 - A phase 1 study of selective XPO1 inhibitor, selinexor, in recurrent and refractory high-grade glioma
	NCT03299309 - Trial evaluating PEP-CMV for recurrent or progressive high-grade glioma
	NCT03478462 - Dose escalation, efficacy, and safety study of CLR 131 radioiodinated therapeutic for relapsed or refractory high-grade glioma
	NCT05934630 - Trial evaluating cell-free tumor DNA in high-grade glioma at any stage of therapy
	NCT04238819 - A phase 1b/2 study of abemaciclib with temozolomide +/- irinotecan with relapsed or refractory high-grade glioma
	NCT04195555 - Phase 2 trial of ivosidenib in IDH1-altered recurrent or refractory high-grade glioma
	NCT03213704 - Phase 2 trial of larotrectinib in NTRK fusion positive relapsed or refractory high-grade glioma

Outcomes

Patients who survive pediatric-type diffuse high-grade gliomas are often left with significant neurocognitive, neuroendocrinologic, and other neurologic deficits as a result of the tumor’s location within the central nervous system. Furthermore, secondary effects can result from surgery, irradiation, and chemotherapy (53). Complications that may arise as a result of either direct tumor effect or the treatment administered include obstructive hydrocephaly, neurologic impairment, radiation-induced effects (neurocognitive decline, endocrinologic dysfunction, mineralizing microangiopathy with ischemia or infarct, secondary CNS malignancies, transient headaches, fatigue, nausea, vomiting, and anorexia), and chemotherapy-induced effects (myelosuppression, infection, nausea, vomiting, anorexia, renal damage, hepatic damage, hearing damage, neurotoxicity, and secondary malignancies). Infertility and impairment of growth may also be long-term sequelae of therapy (18).

References

01: Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010;54(4):519-25. PMID 19852061
02: Bailey P, Cushing H. A classification of tumors of the glioma group. Philadelphia: JB Lippincott, 1926.
03: Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 ef-14 randomized trial. Int J Radiat Oncol Biol Phys 2019;104(5):1106-13. PMID 31026557
04: Bilginer B, Hanalioglu S, Turk CC, et al. Is the knowledge pertained to adult glioblastomas enough for pediatric cases? prognostic factors in childhood. Turk Neurosurg 2017;27(2):279-88. PMID 27593770
05: Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34(19):2206-11. PMID 27001570
06: Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neuroloncol 2006;76(3):313-9. PMID 16200343
07: Cage TA, Mueller S, Haas-Kogan D, Gupta N. High-grade gliomas in children. Neurosurg Clin N Am 2012;23(3):515-23. PMID 22748663
08: Chatwin HV, Cruz Cruz J, Green AL. Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. FEBS J 2021;288(21):6127-41. PMID 33523591
09: Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 2011;13(3):317-23. PMID 21339192
10: Cordier S, Mandereau L, Preston-Martin S, et al. Parental occupations and childhood brain tumors: results of an international case-control study. Cancer Causes Control 2001;12(9):865-74. PMID 11714115
11: Crowell C, Mata-Mbemba D, Bennett J, et al. Systematic review of diffuse hemispheric glioma, H3 G34-mutant: outcomes and associated clinical factors. Neurooncol Adv 2022;4(1):vdac133. PMID 36105387
12: Di Ruscio V, Carai A, Del Baldo G, et al. Molecular landscape in infant high-grade gliomas: a single center experience. Diagnostics (Basel) 2022;12(2):372. PMID 35204463
13: Finlay JL, August C, Packer R, et al. High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. J Neurooncol 1990;9(3):239-48. PMID 1964962
14: Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the 8-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995;13(1):112-23. PMID 7799011
15: Finlay JL, Dhall G, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51(6):806-11. PMID 18802947
16: Finlay JL, Goldman S, Wong MC, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 1996;14(9):2495-503. PMID 8823328
17: Gianno F, Giovannoni I, Cafferata B, et al. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification. Pathologica 2022;114(6):422-35.** PMID 36534421
18: Glod J, Rahme GJ, Kaur H, et al. Pediatric brain tumors: current knowledge and therapeutic opportunities. J Pediatr Hematol Oncol 2016;38(4):249-60. PMID 26989915
19: Green AL, Mulcahy Levy JM, Vibhakar R, et al. Tumor treating fields in pediatric high-grade glioma. Childs Nerv Syst 2017;33(7):1043-5. PMID 28470383
20: Grill J, Massimino M, Bouffet E, et al. Phase II, Open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 2018;36(10):951-8. PMID 29412784
21: Grovas AC, Boyett JM, Lindsley K, Rosenblum M, Yates AJ, Finlay JL. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group. Med Pediatr Oncol 1999;33(2):83-7. PMID 10398181
22: Guerra-Garcia PV, Marshall LV, Cockle JV, et al. Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: a review of past, current, and emerging therapies. Pediatr Blood Cancer 2020;67(1):e28011. PMID 31617673
23: Hu W, Duan H, Zhong S, Zeng J, Mou Y. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope? J Transl Med 2022;20(1):64. PMID 35109850
24: Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol 2016;18(10):1442-50. PMID 27006176
25: Jakacki RI, Jamison C, Mathews VP, et al. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. Med Pediatr Oncol 1998;31(6):483-90. PMID 9835900
26: Johnson JH Jr, Phillips PC. Malignant gliomas in children. Cancer Invest 1996;14(6):609-21. PMID 8951364
27: Josupeit R, Bender S, Kern S, et al. Pediatric and adult high-grade glioma stem cell culture models are permissive to lytic infection with parovirus h-1. Viruses 2016;8(5):138. PMID 27213425
28: Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993;3:255. PMID 8293185
29: Kleihues P, Cavenee W. Pathology and genetics: tumours of the central nervous system. In: Kleiheus P, Sobin L, editors. World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2000.
30: Kornblith P, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988;68:1. PMID 3275753
31: Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20(24):4684-91. PMID 12488414
32: Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131(6):803-20. PMID 27157931
33: Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-51.** PMID 34185076
34: MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro Oncol 2011;13(10):1049-58. PMID 21784756
35: MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer 2005;104(12):2862-71. PMID 16315242
36: Marchese MJ, Chang CH. Malignant astrocytic gliomas in children. Cancer 1990;65:2771-8. PMID 2160318
37: Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008;28(4C):2437-42. PMID 18751431
38: Miklja Z, Yadav VN, Cartaxo RT, et al. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest 2020;130(10):5313-25. PMID 32603316
39: Nussbaumer G, Benesch M, Grabovska Y, et al. Gliomatosis cerebri in children: a poor prognostic phenotype of diffuse gliomas with a distinct molecular profile. Neuro Oncol 2024;26(9):1723-37. PMID 38717379
40: Ocasio JK, Budd KM, Roach JT, Andrews JM, Baker SJ. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma. Cancer Metastasis Rev 2023;42(2):367-88. PMID 37119408
41: Park YW, Vollmuth P, Foltyn-Dumitru M, et al. The 2021 WHO classification for gliomas and implications on imaging diagnosis: part 2-summary of imaging findings on pediatric-type diffuse high-grade gliomas, pediatric-type diffuse low-grade gliomas, and circumscribed astrocytic gliomas. J Magn Reson Imaging 2023;58(3):690-708.** PMID 37069764
42: Perez A, Huse JT. The evolving classification of diffuse gliomas: World Health Organization Updates for 2021. Curr Neurol Neurosci Rep 2021;21(12):67. PMID 34817712
43: Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009;115(24):5761-70. PMID 19813274
44: Reddy AT, Wellons JC 3rd. Pediatric high-grade gliomas. Cancer J 2003;9(2):107-12. PMID 12784876
45: Russell DS, Rubinstein LI. Pathology of tumors of the central nervous system. 5th ed. Baltimore: Williams and Wilkins, 1989.
46: Saran F. Recent advances in paediatric neurooncology. Curr Opin Neurol 2002;15(6):671-7. PMID 12447104
47: Schoenberg B, Glista G, Reagan T. The familial occurrence of glioma. Surg Neurol 1975;3:139. PMID 1124484
48: Shady JA, Black PM, Kupsky WJ, et al. Seizures in children with supratentorial astroglial neoplasms. Pediatr Neurosurg 1994;21(1):23-30. PMID 7947306
49: Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989;7(2):165-77. PMID 2550594
50: Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015;314(23):2535-43. PMID 26670971
51: Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005;5(3):198-206. PMID 15865885
52: Tsai ML, Chen CL, Hsieh KL, et al. Seizure characteristics are related to tumor pathology in children with brain tumors. Epilepsy Res 2018;147:15-21. PMID 30176531
53: Wolfe KR, Walsh KS, Reynolds NC, et al. Executive functions and social skills in survivors of pediatric brain tumor. Child Neuropsychol 2013;19(4):370-84. PMID 22420326
54: Wolff JE, Classen CF, Wagner S, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol 2008;87(2):155-64. PMID 18209954
55: Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010;116(3):705-12. PMID 19957326
56: Zhang H, Liu K, Ba R, et al. Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping. Neuro Oncol 2023;25(6):1146-56. PMID 36617263
57: Zulch KJ. Brain tumors. Their biology and pathology. 3rd ed. Springer Verlag: Berlin Heidelberg, 1986.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Elizabeth Finch MD

Dr. Finch of Penn State Health received consulting fees from DayOne Biopharmaceuticals as an advisory board member.
See Profile

Editor

Roger J Packer MD

Dr. Packer of Children’s National Medical Center and George Washington University has no relevant financial relationships to disclose.
See Profile

Former Authors

Yoko T Udaka MD
Eugene Hwang MD
Emmanuel Mantilla DO
Edward Pan MD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male=female
Heredity: heredity may be a factor (rarely)
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Malignant neoplasm of cerebrum, except lobes and ventricles: C71.0

Malignant neoplasm of frontal lobe: C71.1

Malignant neoplasm of temporal lobe: C71.2

Malignant neoplasm of parietal lobe: C71.3

Malignant neoplasm of occipital lobe: C71.4
ICD-O: Neoplasm, malignant: M800/3

Neoplasm, malignant, uncertain whether primary or metastatic: M8000/9
OMIM: Glioma of brain, familial: #137800

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Pediatric-type diffuse high-grade gliomas (excluding diffuse midline gliomas)

Associated Disorders

Anaplastic astrocytoma
Anaplastic glioma
Diabetes insipidus
Glioblastoma multiforme
Growth hormone deficiency
- High-grade astrocytoma
- High-grade glioma
- Li-Fraumeni syndrome
- Malignant astrocytoma

Differential Diagnosis

other brain tumors
benign glioma
ependymoma
meningioma
choroid plexus tumors
- pineal parenchymal tumors
- neuronal and mixed neuronal glial tumors
- CNS lymphoma
- leukemic meningitis
- craniopharyngioma
- germ cell midline tumors
- teratoma midline tumors
- primary intracranial (skull-based) Ewing sarcoma
- metastatic solid tumor
- arteriovenous malformation
- abscess or parasitic cyst
- demyelinating disease
- subdural effusion
- epidural effusion
- intracranial hemorrhage
- subarachnoid hemorrhage

Other primary brain tumors
	Low-grade glioma Ependymoma Meningioma Choroid plexus tumors (papilloma or carcinoma) Pineal parenchymal tumors (pineoblastoma or pineocytoma) Diffuse midline glioma H3 K27-altered Craniopharyngioma CNS germ cell tumor or non-germinomatous germ cell tumor
Metastatic solid tumor
	Rhabdomyosarcoma Neuroblastoma
Arteriovenous malformation
Abscess or parasitic cyst
Demyelinating disease
Effusion (subdural or epidural)
Hemorrhage (intracranial or subarachnoid)

Pediatric-type diffuse high-grade gliomas (excluding diffuse midline gliomas)

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Table 1. Clinical Trials Available in the United States for Pediatric High-Grade Glioma as of July 31, 2024

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Tumors of the skull base

Breath-holding spells

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Ganglioglioma

Paraneoplastic syndromes

This is an article preview.
Start a Free Account
to access the full version.